Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Provectus Pharmaceuticals has started a multicenter, randomised controlled Phase 2c clinical trial of PH-10 for psoriasis.
Subscribe to our email newsletter
Provectus Pharma expects to recruit up to 90 subjects at four different sites in Phase 2c study, in late December.
In the trial, the subjects will be randomised sequentially by center to one of four treatment cohorts, and will assess efficacy and safety of topical PH-10 applied once daily to areas of mild to moderate plaque psoriasis.
Provectus Pharma CEO Craig Dees said that the results of this study are expected to define the parameters necessary for the design of a pivotal Phase 3 trial, and will be an important milestone on the regulatory pathway leading towards commercialisation.
"In addition, we’ve held discussions with a number of potential outlicensing partners, and we believe this Phase 2c trial will further solidify the commercial viability of PH-10 in these discussions," Dees said.